William Whissell
Psychiatry · Atlanta, GANPI 1881603553
Payments from drug & device makers
Across 298 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$963
- Alkermes, Inc.$755
- Otsuka America Pharmaceutical, Inc.$669
- Indivior Inc.$463
- Neurocrine Biosciences, Inc.$459
- plus $1K from 11 others
What the payments were for
- Food & beverage$5,63498%
- Education$1202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 76 | $1,180 |
| Johnson & Johnson | 54 | $963 |
| Alkermes, Inc. | 38 | $755 |
| Otsuka America Pharmaceutical, Inc. | 35 | $669 |
| Indivior Inc. | 17 | $463 |
| Neurocrine Biosciences, Inc. | 18 | $459 |
| AbbVie(2 entities) | 15 | $277 |
| Sunovion Pharmaceuticals Inc. | 11 | $233 |
| Lundbeck LLC | 10 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $164 |
| Vanda Pharmaceuticals Inc. | 6 | $147 |
| Luye Pharma (USA) Ltd. | 3 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75 |
| Tris Pharma Inc | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
How this compares
$5,754 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 109 | $832,903 |
| Invega SustennaPaliperidone Palmitate | 194 | $582,105 |
| IngrezzaValbenazine Tosylate | 11 | $92,722 |
| Abilify MaintenaAripiprazole | 18 | $51,830 |
| VraylarCariprazine Hcl | 24 | $35,075 |
| Lurasidone Hcl | 72 | $28,487 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $23,120 |
| Paliperidone ErPaliperidone | 60 | $18,597 |
| Aripiprazole | 163 | $13,179 |
| Ziprasidone Hcl | 122 | $10,506 |
| Olanzapine | 241 | $9,793 |
| Divalproex Sodium ErDivalproex Sodium | 166 | $6,511 |
| Clozapine | 61 | $3,505 |
| Haloperidol Decanoate | 62 | $3,251 |
| Quetiapine Fumarate | 149 | $3,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $963 | $1,415,008303 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $459 | $92,72211 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $669 | $51,83018 claims |
| AbbVieVraylar | $277 | $35,07524 claims |
| Alkermes, Inc.Lybalvi | $755 | $23,12013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Bethany DavisAtlanta$4.4M
- Patricio Riva PosseAtlanta$884K
- Kerry ResslerAtlanta$365K
- Boadie DunlopAtlanta$345K
- Michael BurkeAtlanta$328K
- Bryon EvansAtlanta$211K
- Nurul HoqueAtlanta$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.